Profile

Procarta Biosystems

Procarta Biosystems is a spin-out from one of Europe’s leading microbiology departments at the John Innes Centre. The company, formed in early 2008, is investigating a novel approach to counter antibiotic resistance and defeat infectious diseases using a DNA decoy technique, which aims to restore antibiotic efficacy against resistant superdrugs, such as methicillin-resistent Staphylococcus aureus (MRSA) and vancomycin-resistant Entercoccus (VRE).

Accessing the skills in the John Innes Centre, Procarta is also able to offer a contract research service creating and improving Streptomyces strains for heterologous production.

Status current

Associated Fund Rainbow Seed Fund

Sector Medical / Biotechnology

Website www.procartabio.com/

Associated Team Members

Relevant News

Antibiotics and the Gut Microbiome

A study recently published in Nature Communications (30 June) has shown that even small...

read more

ICNN 2015 : 17th International Conference on Nanotechnology and Nanomedicine

Clara Franch de la Cal will be representing Procarta Biosystems at the 17th International Conference...

read more

Procarta Biosystems joins BEAM Alliance

The BEAM Alliance is working “to improve the regulatory, investment, and commercial environments in...

read more

MRSA superbug found in British pork

Evidence is mounting for the risk we are placing ourselves at through overuse of...

read more

MRSA superbug found in British pork

Evidence is mounting for the risk we are placing ourselves at through overuse of...

read more

Review on Antimicrobial Resistance (AMR): Securing New Drugs

Chaired by Jim O’Neil this third paper on antimicrobial resistance published in May 2015...

read more

More Companies in Medical / Biotechnology